ABEONA THERAPEUTICS INC.(ABEO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ABEONA THERAPEUTICS INC. (ABEO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABEO at 23.7/100 on a 32-signal composite quality model, placing it at rank #2,716 of 2,961 stocks — the bottom half of the AI-ranked universe. ABEO scores in the top quartile across revenue growth (96.7). Areas of concern include free cash flow (3.3) and revenue scale (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ABEONA THERAPEUTICS INC. reports quarterly revenue of $11.4M, net income of $-20.2M, free cash flow of $-18.0M. Top institutional holders of ABEO by reported 13-F value include Nantahala Capital Management, BlackRock, Cable Car Capital, based on the most recent SEC filings. ABEO trades on the Nasdaq exchange and files with the SEC under CIK 318306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABEO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABEONA THERAPEUTICS INC. directly from SEC EDGAR.